The Supreme Court on Wednesday refused to let the Trump administration immediately enforce new restrictions on medical care and social accommodations for transgender people in federal prisons, preserving a nationwide injunction while the government’s appeal continues. The brief order denied the administration’s request without explanation; Justices Clarence Thomas and Samuel Alito said they would have granted it.

The decision in Trump v. Kingdom is temporary and does not resolve whether the Bureau of Prisons’ policy is lawful. Its immediate effect, however, is concrete: the bureau must continue providing hormone therapy and certain social accommodations under the practices that existed before President Donald Trump’s January 2025 directive, according to the agency’s own compliance guidance.

What the Court decided

The administration asked the justices to pause a District of Columbia federal judge’s injunction while the case proceeds through the U.S. Court of Appeals for the D.C. Circuit. Chief Justice John Roberts referred the request to the full Court, which denied it on October 21. Because the order contains no reasoning, it does not establish a new constitutional rule or forecast how the justices would decide the case after full briefing.

That limited posture matters. The justices did not order the government to adopt a permanent policy, rule on the plaintiffs’ Eighth Amendment claims, or decide the ultimate limits of prison administrators’ discretion. They simply declined to suspend the lower court’s interim relief. The injunction therefore remains the controlling operational rule for now.

How the policy changed

The dispute began with a January 20, 2025, executive order directing the attorney general to revise prison medical policy and prevent federal funds from being used for procedures, treatments or drugs intended to align an inmate’s appearance with a gender different from sex at birth. The Bureau of Prisons followed with implementing memoranda and, in February 2026, a broader program statement for inmates diagnosed with gender dysphoria.

Under the 2026 policy, the bureau said it would continue psychotherapy, group counseling, psychiatric services and medication for related mental-health needs. But it generally would not provide gender-transition surgery, would not begin hormone therapy for newly diagnosed inmates, would taper hormones for many people already receiving them, and would end items or accommodations such as makeup, wigs and certain clothing. The agency described the approach as an independent judgment informed by medical literature, security concerns and the correctional setting.

In its stay application, the Justice Department argued that the bureau assembled a 3,200-page administrative record and a 43-page explanation supporting the new policy. It said prison officials reasonably concluded that some interventions were not medically necessary and could create safety, security or administrative problems. The government also argued that the injunction exceeded limits imposed by the Prison Litigation Reform Act and improperly displaced agency expertise.

The plaintiffs—three inmates representing a certified class of people in federal custody who have or later receive a gender-dysphoria diagnosis—argued that abruptly withdrawing prescribed treatment and accommodations could cause serious physical and psychological harm. U.S. District Judge Royce Lamberth’s original opinion found that they were likely to succeed on their Administrative Procedure Act claim because the bureau had not adequately explained its reversal. Later orders addressed the bureau’s revised 2026 policy and kept classwide protection in place.

The government says the revised policy corrected the procedural and evidentiary problems identified by the judge. The challengers maintain that the updated record still does not justify replacing individualized clinical decisions with a categorical restriction. The Supreme Court’s silence leaves that disagreement for the lower courts.

Who is affected now

The injunction applies to a nationwide class, not only the three named plaintiffs. The Bureau of Prisons instructed staff that they remain obligated to provide hormones and social accommodations under the pre-2025 framework while the injunction is active. That guidance also illustrates the unusual split inside the agency’s rules: the 2026 policy exists on paper, but the court order prevents officials from applying central portions of it to the protected class.

The number of people directly affected depends on the measure used. AP reported that about 600 inmates were receiving hormone therapy in 2025, citing court records. The certified class is broader because it includes current and future federal prisoners diagnosed with gender dysphoria, whether or not they were already receiving hormones.

What comes next

The merits appeal remains before the D.C. Circuit. That court can review whether the bureau offered a reasoned explanation for its policy change, whether the injunction complies with federal limits on prison litigation, and whether the district judge gave appropriate weight to correctional officials’ judgments. A later ruling could narrow, lift or preserve the injunction, and the losing side could then seek Supreme Court review through the ordinary process.

For now, the practical policy is the status quo required by the lower court: treatment and covered accommodations continue while judges assess the legality of the government’s reversal. The Supreme Court’s refusal to intervene is notable because it leaves a nationwide constraint on an administration policy in force, but it is not a final endorsement of the plaintiffs’ claims. The central questions—how much evidence an agency needs to reverse longstanding medical practice and how courts should balance that evidence against prison-management authority—remain unresolved.